The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.

Antineoplastic Agents / therapeutic use Biopsy Breast Neoplasms / drug therapy Cell Cycle Proteins / antagonists & inhibitors Cell Line, Tumor Checkpoint Kinase 1 Drug Resistance, Neoplasm / genetics Female Genomics Humans Protein Kinase Inhibitors / therapeutic use Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins p21(ras) Receptors, Steroid / genetics Retinoblastoma Binding Proteins Ubiquitin-Protein Ligases Exome Sequencing

Journal

Cancer discovery

ISSN: 2159-8290

Titre abrégé: Cancer Discov

Pays: United States

ID NLM: 101561693

Informations de publication

Date de publication:
08 2020

Historique:

received: 27 11 2019

revised: 29 03 2020

accepted: 08 05 2020

pubmed: 15 5 2020

medline: 30 11 2021

entrez: 15 5 2020

Statut: ppublish

Résumé

Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR

Identifiants

DOI: 10.1158/2159-8290.CD-19-1390 PMID: 32404308 PMC: PMC8815415

pubmed: 32404308

pii: 2159-8290.CD-19-1390

doi: 10.1158/2159-8290.CD-19-1390

pmc: PMC8815415

mid: NIHMS1594850

doi:

Substances chimiques

Antineoplastic Agents 0

Cell Cycle Proteins 0

Protein Kinase Inhibitors 0

RB1 protein, human 0

Receptors, Steroid 0

Retinoblastoma Binding Proteins 0

Ubiquitin-Protein Ligases EC 2.3.2.27

AKT1 protein, human EC 2.7.11.1

CHEK1 protein, human EC 2.7.11.1

Checkpoint Kinase 1 EC 2.7.11.1

Proto-Oncogene Proteins c-akt EC 2.7.11.1

Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

Pagination

1174-1193

Subventions

Organisme : NCI NIH HHS

ID : K12 CA090625

Pays : United States

Organisme : NCI NIH HHS

ID : P50 CA168504

Pays : United States

Informations de copyright

Références

J Clin Oncol. 2016 May 20;34(15):1764-71

pubmed: 27044938

Nat Biotechnol. 2013 Mar;31(3):213-9

pubmed: 23396013

Clin Cancer Res. 2019 Nov 1;25(21):6443-6451

pubmed: 31371343

Clin Cancer Res. 2017 Sep 1;23(17):5218-5224

pubmed: 28533223

Clin Cancer Res. 2015 Nov 1;21(21):4780-5

pubmed: 26362996

Lancet Oncol. 2016 Apr;17(4):425-439

pubmed: 26947331

Genome Biol. 2011;12(1):R1

pubmed: 21205303

Ann Oncol. 2017 Dec 1;28(12):3076-3082

pubmed: 28950321

Oncotarget. 2016 Jan 12;7(2):1380-94

pubmed: 26595527

Bioinformatics. 2012 Jul 15;28(14):1811-7

pubmed: 22581179

Oncol Rep. 2010 Feb;23(2):307-12

pubmed: 20043089

Nat Rev Clin Oncol. 2015 Oct;12(10):573-83

pubmed: 26122181

Ann Oncol. 2018 Mar 1;29(3):640-645

pubmed: 29236940

PLoS One. 2014 May 09;9(5):e96995

pubmed: 24816249

Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947

pubmed: 30371878

Cancer Res. 2017 May 1;77(9):2488-2499

pubmed: 28249908

Clin Cancer Res. 2020 Nov 15;26(22):5974-5989

pubmed: 32723837

Cancer Cell. 2018 Dec 10;34(6):893-905.e8

pubmed: 30537512

Nat Biotechnol. 2012 May;30(5):413-21

pubmed: 22544022

Oncogene. 2017 Apr 20;36(16):2255-2264

pubmed: 27748766

N Engl J Med. 2016 Nov 3;375(18):1738-1748

pubmed: 27717303

Nat Commun. 2017 Nov 6;8(1):1324

pubmed: 29109393

Cell Div. 2018 Sep 19;13:7

pubmed: 30250494

J Clin Oncol. 2017 Nov 10;35(32):3638-3646

pubmed: 28968163

Breast Cancer Res. 2009;11(5):R77

pubmed: 19874578

Nat Genet. 2006 May;38(5):500-1

pubmed: 16642009

EBioMedicine. 2015 Mar 06;2(5):421-31

pubmed: 26137586

Genet Med. 2017 Feb;19(2):192-203

pubmed: 27532257

J Pathol. 2017 Feb;241(3):405-419

pubmed: 27925203

Cell Rep. 2019 Mar 5;26(10):2667-2680.e7

pubmed: 30840889

Nat Med. 2014 Jun;20(6):682-8

pubmed: 24836576

J Clin Oncol. 2016 Sep 1;34(25):2961-8

pubmed: 27269946

N Engl J Med. 2019 Jul 25;381(4):307-316

pubmed: 31166679

Nat Commun. 2019 Mar 26;10(1):1373

pubmed: 30914635

Cancer Discov. 2020 Jan;10(1):72-85

pubmed: 31594766

Lancet Oncol. 2015 Jan;16(1):25-35

pubmed: 25524798

Nat Med. 2017 Jun;23(6):703-713

pubmed: 28481359

Cancer Discov. 2019 Feb;9(2):248-263

pubmed: 30373917

Curr Oncol Rep. 2019 Feb 26;21(3):25

pubmed: 30806829

Nat Methods. 2014 Apr;11(4):396-8

pubmed: 24633410

Cancer Discov. 2018 Nov;8(11):1390-1403

pubmed: 30206110

J Clin Oncol. 2019 May 10;37(14):1169-1178

pubmed: 30807234

Front Oncol. 2018 Aug 10;8:308

pubmed: 30148117

JAMA Oncol. 2020 Jan 1;6(1):116-124

pubmed: 31563959

Nat Genet. 2011 May;43(5):491-8

pubmed: 21478889

Nucleic Acids Res. 2013 Apr 1;41(6):e67

pubmed: 23303777

Nat Commun. 2016 Jun 22;7:12008

pubmed: 27328849

Breast Cancer Res Treat. 2018 Apr;168(3):639-647

pubmed: 29289986

Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489-94

pubmed: 24218601

Bioinformatics. 2011 Sep 15;27(18):2601-2

pubmed: 21803805

Cancer Discov. 2019 Feb;9(2):230-247

pubmed: 30373918

Biostatistics. 2004 Oct;5(4):557-72

pubmed: 15475419

Cancer Res. 2015 Sep 15;75(18):3980-90

pubmed: 26249178

Cancer Res. 2016 Apr 15;76(8):2301-13

pubmed: 27020857

N Engl J Med. 2016 Nov 17;375(20):1925-1936

pubmed: 27959613

Hum Mutat. 2015 Apr;36(4):E2423-9

pubmed: 25703262

Genome Res. 2018 Apr;28(4):581-591

pubmed: 29535149

J Biol Chem. 2013 Dec 27;288(52):36856-62

pubmed: 24247240

J Clin Oncol. 2017 Sep 1;35(25):2875-2884

pubmed: 28580882

Nat Genet. 2019 Feb;51(2):207-216

pubmed: 30531871

Mol Cancer Ther. 2012 Jul;11(7):1488-99

pubmed: 22564725